Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
about
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisReview of Journal of Cardiovascular Magnetic Resonance 2012.Review of Journal of Cardiovascular Magnetic Resonance 2013National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.Endogenous assessment of chronic myocardial infarction with T(1ρ)-mapping in patientsAn Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging.Pseudoaneurysm of the mitral-aortic intervalvular fibrosa presenting after chest trauma and diagnosed by cardiac magnetic resonance: a case report.Quantification of the plasma clearance kinetics of a gadolinium-based contrast agent by photoinduced triplet harvesting.Myocardial Viability on Cardiac Magnetic Resonance.Cost-effectiveness of cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary artery disease in Germany.Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI.Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium.
P2860
Q30278095-79F5F48C-23B0-4B23-B734-81C3ED6CC8D6Q30446298-5C345832-5640-4FD5-B8CD-768F285B0A5DQ30487473-483EAEFC-EE77-4DCA-AE97-E1048A623772Q31039888-23D35E9A-1ACA-41C4-A612-07732EE35B9BQ34746688-BE02193B-A144-4979-915F-E4662C04DB4BQ35664137-51EAB315-5C70-4BA3-AB40-517F3667D12FQ35966583-20FA7897-E2C2-49D5-9FEF-615430BDAA16Q36380266-FB5A0BE6-33DC-4AF9-8C56-3FDB9E45C60EQ41779796-4C9B7E17-6CA9-4A6D-8CE9-EEE141AA285AQ42244547-C0E216CA-7102-418B-9981-F41F1D5F55C9Q43120081-EB85AD02-9FBD-4D6E-BFE4-F6DA5F0B4C35Q53070131-6556ACC7-C99C-4A67-BECC-1834C64490F6Q55344504-F5A5EC00-B35A-4994-BB54-D7B961C4A920
P2860
Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@ast
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@en
Gadolinium-enhanced cardiovasc ...... s Food and Drug Administration
@nl
type
label
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@ast
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@en
Gadolinium-enhanced cardiovasc ...... s Food and Drug Administration
@nl
prefLabel
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@ast
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@en
Gadolinium-enhanced cardiovasc ...... s Food and Drug Administration
@nl
P2860
P31
P50
P921
P356
P1476
Gadolinium-enhanced cardiovasc ...... ministration (FDA) guidelines.
@en
P2093
Joao A C Lima
P2860
P2888
P356
10.1186/1532-429X-14-18
P5008
P577
2012-02-29T00:00:00Z
P5875
P6179
1051479478